Third phase III trial of netupitant/palonosetron for the prevention of chemotherapy-induced nausea and vomiting.

Trial Profile

Third phase III trial of netupitant/palonosetron for the prevention of chemotherapy-induced nausea and vomiting.

Not stated
Phase of Trial: Phase III

Latest Information Update: 30 May 2013

At a glance

  • Drugs Netupitant/palonosetron (Primary)
  • Indications Chemotherapy-induced nausea and vomiting
  • Focus Registrational; Therapeutic Use
  • Sponsors Helsinn Healthcare SA
  • Most Recent Events

    • 30 May 2013 Status changed from not yet recruiting to unconfirmed; it is not known if this trial was commenced.
    • 27 Sep 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top